Cystic fibrosis antibiotic dosing: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
+ | {| class="wikitable sortable" |
||
− | {| |
||
! Medication |
! Medication |
||
+ | !Coverage |
||
! Dose |
! Dose |
||
− | ! Frequency |
||
− | ! Home IV |
||
|- |
|- |
||
− | | Aztreonam |
+ | | [[Aztreonam]] |
+ | |[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
⚫ | |||
− | | q8h |
+ | | 2 g IV q8h |
− | | no |
||
|- |
|- |
||
− | | Cefazolin |
+ | | [[Cefazolin]] |
+ | |[[Staphylococcus aureus]] |
||
− | | 2 g |
||
− | | q8h |
+ | | 2 g IV q8h |
− | | yes |
||
|- |
|- |
||
− | | Cefipime |
+ | | [[Cefipime]] |
+ | |[[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
− | | 2 g |
||
− | | q8h |
+ | | 2 g IV q8h |
− | | yes |
||
|- |
|- |
||
− | | Ceftazidime |
+ | | [[Ceftazidime]] |
+ | |[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
− | | 2 g |
||
+ | | 2-3 g IV q6-8h (max 12 g/day) |
||
− | | q8h |
||
− | | yes |
||
|- |
|- |
||
+ | |[[Ceftazidime-avibactam]] |
||
⚫ | |||
+ | |[[Pseudomonas aeruginosa]] |
||
− | | 500 mg to 1 g |
||
+ | |2.5 g IV q8h |
||
− | | q6h |
||
− | | at SMH |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Achromobacter]], [[Burkholderia cepacia]] |
||
− | | 400 mg |
||
+ | | 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
||
− | | q8h |
||
− | | yes |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
− | | 2 g |
||
+ | | 400 mg IV q8h or 750 mg p.o. BID to TID |
||
− | | q6h |
||
− | | yes |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Staphylococcus aureus]] |
||
− | | 75 mg |
||
+ | | 1-2 g IV q6h |
||
− | | q8-12h |
||
− | | yes |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
− | | 2 g |
||
+ | | 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
||
− | | q8h |
||
− | | CADD pump |
||
|- |
|- |
||
⚫ | |||
− | | Pip/tazo |
||
+ | |[[Achromobacter]], [[Burkholderia cepacia]], [[Pseudomonas aeruginosa]] |
||
⚫ | |||
⚫ | |||
− | | q6-8h |
||
− | | yes |
||
|- |
|- |
||
+ | | [[Piperacillin/tazobactam]] |
||
⚫ | |||
+ | |[[Achromobacter]], [[Pseudomonas aeruginosa]] |
||
⚫ | |||
⚫ | |||
− | | q12h |
||
− | | no |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Achromobacter]], [[MRSA]], [[NTM]], [[Stenotrophomonas maltophilia]] |
||
− | | 10 mg/kg |
||
⚫ | |||
− | | q24h |
||
− | | yes |
||
|- |
|- |
||
⚫ | |||
⚫ | |||
+ | |[[Pseudomonas aeruginosa]] |
||
− | | 1 g |
||
+ | | 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
||
− | | q8h |
||
+ | |- |
||
− | | yes |
||
⚫ | |||
+ | |[[MRSA]] |
||
+ | | 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
||
|} |
|} |
||
+ | Source: [https://www.cysticfibrosis.ca/uploads/Antibiotic%20Dosing%20Guideline%20Aug%202021.pdf CF Canada] |
||
− | '''Source:''' St. Michael's Hospital |
||
[[Category:Infectious diseases]] |
[[Category:Infectious diseases]] |
Latest revision as of 11:29, 20 June 2023
Medication | Coverage | Dose |
---|---|---|
Aztreonam | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Cefazolin | Staphylococcus aureus | 2 g IV q8h |
Cefipime | Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Ceftazidime | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2-3 g IV q6-8h (max 12 g/day) |
Ceftazidime-avibactam | Pseudomonas aeruginosa | 2.5 g IV q8h |
Chloramphenicol | Achromobacter, Burkholderia cepacia | 12.5-25 mg/kg/dose IV q6h (max 1g/dose) with drug monitoring to target peak 10-20 mcg/mL and trough 5-10 mcg/mL |
Ciprofloxacin | Achromobacter, Pseudomonas aeruginosa | 400 mg IV q8h or 750 mg p.o. BID to TID |
Cloxacillin | Staphylococcus aureus | 1-2 g IV q6h |
Colistin | Achromobacter, Pseudomonas aeruginosa | 2.5-5 mg/kg/day divided q8-12h (max 5 mg/kg/day) |
Meropenem | Achromobacter, Burkholderia cepacia, Pseudomonas aeruginosa | 2 g IV q8h |
Piperacillin/tazobactam | Achromobacter, Pseudomonas aeruginosa | 4.5 g IV q4-6h |
Tigecycline | Achromobacter, MRSA, NTM, Stenotrophomonas maltophilia | 100 mg IV load, then 50 mg IV q12h |
Tobramycin | Pseudomonas aeruginosa | 10 mg/kg/dose IV q24h with drug monitoring to target peak 20-40 mg/L and trough <1 mg/L |
Vancomycin | MRSA | 15-20 mg/kg/dose IV q8-12h to target trough 15-20 mg/L; or 15-20 mg/kg IV load then 30-40 mg/kg/day (max 60 mg/kg/day) IV continuous infusion, target steady state level 20-25 mg/L |
Source: CF Canada